Simona Colla
Overview
Explore the profile of Simona Colla including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
4841
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gurashi K, Wang Y, Amaral F, Spence K, Cant R, Yao C, et al.
Cell Rep Med
. 2025 Feb;
6(2):101933.
PMID: 39892394
Approximately 30% of patients with chronic myelomonocytic leukemia (CMML) undergo transformation to a chemo-refractory blastic phase (BP-CMML). Seeking novel therapeutic approaches, we profiled blast transcriptomes from 42 BP-CMMLs, observing extensive...
2.
Rodriguez-Sevilla J, Adema V, Chien K, Loghavi S, Ma F, Yang H, et al.
Nat Commun
. 2024 Nov;
15(1):9840.
PMID: 39537648
In myelodysplastic syndromes (MDS), the IL-1β pathway is upregulated, and previous studies using mouse models of founder MDS mutations demonstrated that it enhances hematopoietic stem and progenitor cells' (HSPCs') aberrant...
3.
Rodriguez-Sevilla J, Colla S
Semin Hematol
. 2024 Oct;
61(6):385-396.
PMID: 39424469
Inflammation is a key driver of the progression of preleukemic myeloid conditions, such as clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of undetermined significance (CCUS), to myelodysplastic syndromes...
4.
Gutierrez-Rodrigues F, Groarke E, Thongon N, Rodriguez-Sevilla J, Catto L, Niewisch M, et al.
Blood
. 2024 Sep;
144(23):2402-2416.
PMID: 39316766
Telomere biology disorders (TBDs), caused by pathogenic germ line variants in telomere-related genes, present with multiorgan disease and a predisposition to cancer. Clonal hematopoiesis (CH) as a marker of cancer...
5.
Kumar B, Singh A, Basar R, Uprety N, Li Y, Fan H, et al.
Sci Transl Med
. 2024 Sep;
16(764):eadp0004.
PMID: 39259809
Myelodysplastic syndrome and acute myeloid leukemia (AML) belong to a continuous disease spectrum of myeloid malignancies with poor prognosis in the relapsed/refractory setting necessitating novel therapies. Natural killer (NK) cells...
6.
Chakraborty S, Morganti C, Pena B, Zhang H, Verma D, Zaldana K, et al.
bioRxiv
. 2024 Aug;
PMID: 39211137
Statement Of Purpose: Five-year survival from AML is dismal at 30%. Our prior research demonstrated STAT3 over-expression in AML HSPC's to be associated with inferior survival. We now explore STAT3...
7.
Marchesini M, Gherli A, Simoncini E, Moron Dalla Tor L, Montanaro A, Thongon N, et al.
Nat Commun
. 2024 Jun;
15(1):4739.
PMID: 38834613
The overexpression of the ecotropic viral integration site-1 gene (EVI1/MECOM) marks the most lethal acute myeloid leukemia (AML) subgroup carrying chromosome 3q26 abnormalities. By taking advantage of the intersectionality of...
8.
Uryu H, Saeki K, Haeno H, Kapadia C, Furudate K, Nangalia J, et al.
bioRxiv
. 2024 Jun;
PMID: 38826462
Normal hematopoietic stem and progenitor cells (HSPCs) inherently accumulate somatic mutations and lose clonal diversity with age, processes implicated in the development of myeloid malignancies . The impact of exogenous...
9.
Montalban-Bravo G, Thongon N, Rodriguez-Sevilla J, Ma F, Ganan-Gomez I, Yang H, et al.
Cell Rep Med
. 2024 May;
5(6):101585.
PMID: 38781960
RAS pathway mutations, which are present in 30% of patients with chronic myelomonocytic leukemia (CMML) at diagnosis, confer a high risk of resistance to and progression after hypomethylating agent (HMA)...
10.
Rodriguez-Sevilla J, Ganan-Gomez I, Ma F, Chien K, Del Rey M, Loghavi S, et al.
Nat Commun
. 2024 Mar;
15(1):2428.
PMID: 38499526
The molecular mechanisms of venetoclax-based therapy failure in patients with acute myeloid leukemia were recently clarified, but the mechanisms by which patients with myelodysplastic syndromes (MDS) acquire secondary resistance to...